Literature DB >> 24980937

Lambrolizumab induced central nervous system (CNS) toxicity.

Jacob J Mandel1, Adriana Olar2, Kenneth D Aldape2, Ivo W Tremont-Lukats2.   

Abstract

Entities:  

Keywords:  Cancer neurology; Drug toxicity; Immunotherapy; Lambrolizumab; Neuro-oncology

Mesh：

Substances：

Year:  2014        PMID： 24980937      PMCID： PMC4157634          DOI： 10.1016/j.jns.2014.06.023

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN： 0022-510X            Impact factor:   3.181


× No keyword cloud information.
  4 in total

1.  Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors.

Authors:  Amita Patnaik; S Peter Kang; Drew Rasco; Kyriakos P Papadopoulos; Jeroen Elassaiss-Schaap; Muralidhar Beeram; Ronald Drengler; Cong Chen; Lon Smith; Guillermo Espino; Kevin Gergich; Liliana Delgado; Adil Daud; Jill A Lindia; Xiaoyun Nicole Li; Robert H Pierce; Jennifer H Yearley; Dianna Wu; Omar Laterza; Manfred Lehnert; Robert Iannone; Anthony W Tolcher
Journal:  Clin Cancer Res       Date:  2015-05-14       Impact factor: 12.531

2.  Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma.

Authors:  Bing Liao; Sheetal Shroff; Carlos Kamiya-Matsuoka; Sudhakar Tummala
Journal:  Neuro Oncol       Date:  2014-01-30       Impact factor: 12.300

3.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Authors:  Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

4.  Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.

Authors:  Omid Hamid; Caroline Robert; Adil Daud; F Stephen Hodi; Wen-Jen Hwu; Richard Kefford; Jedd D Wolchok; Peter Hersey; Richard W Joseph; Jeffrey S Weber; Roxana Dronca; Tara C Gangadhar; Amita Patnaik; Hassane Zarour; Anthony M Joshua; Kevin Gergich; Jeroen Elassaiss-Schaap; Alain Algazi; Christine Mateus; Peter Boasberg; Paul C Tumeh; Bartosz Chmielowski; Scot W Ebbinghaus; Xiaoyun Nicole Li; S Peter Kang; Antoni Ribas
Journal:  N Engl J Med       Date:  2013-06-02       Impact factor: 91.245
  4 in total
  22 in total

Review 1.  Are BiTEs the "missing link" in cancer therapy?

Authors:  Carter M Suryadevara; Patrick C Gedeon; Luis Sanchez-Perez; Terence Verla; Christopher Alvarez-Breckenridge; Bryan D Choi; Peter E Fecci; John H Sampson
Journal:  Oncoimmunology       Date:  2015-04-30       Impact factor: 8.110

Review 2.  Proposed diagnostic and treatment paradigm for high-grade neurological complications of immune checkpoint inhibitors.

Authors:  Dustin Anderson; Grayson Beecher; Nabeela Nathoo; Michael Smylie; Jennifer A McCombe; John Walker; Rajive Jassal
Journal:  Neurooncol Pract       Date:  2018-10-04

Review 3.  Pembrolizumab in the management of metastatic melanoma.

Authors:  Lavinia Spain; Eugenie Younger; Emine Hatipoglu; James Larkin
Journal:  Melanoma Manag       Date:  2015-11-12

Review 4.  Checkpoint Inhibitors.

Authors:  Lucie Heinzerling; Enrico N de Toni; Georg Schett; Gheorghe Hundorfean; Lisa Zimmer
Journal:  Dtsch Arztebl Int       Date:  2019-02-22       Impact factor: 5.594

Review 5.  Limitations and opportunities for immune checkpoint inhibitors in pediatric malignancies.

Authors:  Jeong A Park; Nai-Kong V Cheung
Journal:  Cancer Treat Rev       Date:  2017-06-01       Impact factor: 12.111

Review 6.  Neurologic Immune-Related Adverse Events Associated with Immune Checkpoint Inhibition.

Authors:  Peter Chei-Way Pan; Aya Haggiagi
Journal:  Curr Oncol Rep       Date:  2019-11-27       Impact factor: 5.075

7.  Neurological Complications Associated With Anti-Programmed Death 1 (PD-1) Antibodies.

Authors:  Justin C Kao; Bing Liao; Svetomir N Markovic; Christopher J Klein; Elie Naddaf; Nathan P Staff; Teerin Liewluck; Julie E Hammack; Paola Sandroni; Heidi Finnes; Michelle L Mauermann
Journal:  JAMA Neurol       Date:  2017-10-01       Impact factor: 18.302

8.  Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis.

Authors:  James Larkin; Bartosz Chmielowski; Christopher D Lao; F Stephen Hodi; William Sharfman; Jeffrey Weber; Karijn P M Suijkerbuijk; Sergio Azevedo; Hewei Li; Daniel Reshef; Alexandre Avila; David A Reardon
Journal:  Oncologist       Date:  2017-05-11

9.  Nivolumab-Associated Acute Demyelinating Encephalitis: A Case Report and Literature Review.

Authors:  Zubair Zafar; Carrie Vogler; Tamer Hudali; Mukul Bhattarai
Journal:  Clin Med Res       Date:  2019-06

Review 10.  Neurological Adverse Events Associated with Immune Checkpoint Inhibitors: Diagnosis and Management.

Authors:  Christophoros Astaras; Rita de Micheli; Bianca Moura; Thomas Hundsberger; Andreas F Hottinger
Journal:  Curr Neurol Neurosci Rep       Date:  2018-02-01       Impact factor: 5.081
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.